首页PHS • FRA
add
Photocure ASA
市场资讯
财务信息
损益表
收入
净收入
| (NOK) | 2024年9月info | 年同比变化 |
|---|---|---|
收入 | 1.20亿 | 11.79% |
经营支出 | 1.15亿 | 9.62% |
净收入 | -346.60万 | 27.61% |
净利润率 | -2.88 | 35.28% |
每股收益 | -0.13 | 27.78% |
息税折旧摊销前利润 | 502.80万 | 50.58% |
有效税率 | 29.87% | — |
资产负债表
总资产
负债总额
| (NOK) | 2024年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 2.91亿 | 14.11% |
总资产 | 7.20亿 | 2.11% |
负债总额 | 2.21亿 | -6.73% |
权益总额 | 5.00亿 | — |
发行在外的股份 | 2710.57万 | — |
市净率 | 0.23 | — |
资产回报率 | -0.76% | — |
资本回报率 | -1.05% | — |
现金流
现金净变动
| (NOK) | 2024年9月info | 年同比变化 |
|---|---|---|
净收入 | -346.60万 | 27.61% |
来自运营的现金 | 3452.90万 | 298.30% |
投资现金 | 242.60万 | 196.27% |
融资现金 | -1289.70万 | -28.49% |
现金净变动 | 2405.70万 | 718.75% |
自由现金流 | 2514.06万 | 5,846.43% |
简介
Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy. Wikipedia
成立时间
1993
员工数量
102
